General Gynecology
Cohort Study | Long-term health consequences after ovarian removal at benign hysterectomy
3 May, 2023 | 14:58h | UTCLong-Term Health Consequences After Ovarian Removal at Benign Hysterectomy: A Nationwide Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)
AUA/SUFU Guideline | Updates to surgical treatment of female stress urinary incontinence
2 May, 2023 | 13:43h | UTC
SR | Cranberries can prevent recurrent urinary tract infections in selected patients
25 Apr, 2023 | 14:41h | UTCCranberries for preventing urinary tract infections – Cochrane Library
Summary: Cranberries for preventing urinary tract infections – Cochrane Library
Commentaries:
Cranberry juice can prevent recurrent UTIs, but only for some people – The Conversation
Review confirms that cranberry products help prevent urinary tract infections – News Medical
Study suggests that routine axillary scanning in diagnostic breast ultrasound has limited impact on cancer detection
19 Apr, 2023 | 13:06h | UTCTo scan or not to scan: effect of scanning the axilla of all patients undergoing diagnostic breast ultrasound – Clinical Imaging (link to abstract – $ for full-text)
Commentary: Is scanning the axilla during diagnostic breast ultrasound necessary? – Health Imaging
M-A | Self-sampling strategies in populations at risk of Chlamydia trachomatis and Neisseria gonorrhoeae
18 Apr, 2023 | 13:09h | UTC
Commentary on Twitter
#OnlineFirst https://t.co/hOPwxJ2SLD
Vialard et al ➡️ diagnostic accuracy of self-sampling followed by CT/GC NAAT was similar to clinician-collected for extragenital sites in high-income countries. Vaginal self-sampling for women in low-income countries had lower accuracy. pic.twitter.com/lIzbQPufJl
— STI_BMJ (@STI_BMJ) April 11, 2023
RCT | Safety of Fezolinetant for vasomotor symptoms associated with menopause
17 Apr, 2023 | 12:54h | UTCRelated:
RCT | Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause
RCT | Efficacy of Fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause
M-A | The risk of long-term cardiometabolic disease in women with premature or early menopause
11 Apr, 2023 | 13:59h | UTC
Review | Urinary incontinence and pelvic organ prolapse in women
10 Apr, 2023 | 13:27h | UTC
Review | Comprehensive care of women with genetic predisposition to breast and ovarian cancer
5 Apr, 2023 | 13:32h | UTC
M-A | Vaginal swab outperforms urine for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis
5 Apr, 2023 | 13:23h | UTC
Consensus Paper | Definition and criteria for diagnosing cesarean scar disorder
5 Apr, 2023 | 12:51h | UTCDefinition and Criteria for Diagnosing Cesarean Scar Disorder – JAMA Network Open
SR | Adding ultrasound to mammography increases breast cancer detection, but increases false-positives and biopsies
3 Apr, 2023 | 13:55h | UTCSummary: The systematic review examined the effectiveness and safety of combining mammography with breast ultrasonography versus mammography alone for breast cancer screening in women at average risk. The research included one randomized controlled trial, two prospective cohort studies, and five retrospective cohort studies, involving a total of 209,207 women.
High certainty evidence from one trial indicated that combining mammography with ultrasonography led to the detection of more breast cancer cases than mammography alone (5 vs. 3 per 1000 women). However, this combination also led to a higher number of false-positive results and biopsies. For every 1000 women screened with the combined approach, 37 more received a false-positive result, and 27 more women underwent a biopsy.
Secondary analysis of the trial data revealed that in women with dense breasts, the combined screening detected more cancer cases than mammography alone, while cohort studies for women with non-dense breasts showed no statistically significant difference between the two screening methods.
The included studies did not analyze whether the higher number of detected cancers with the combined screening method resulted in lower mortality rates compared to mammography alone. Further research, including randomized controlled trials or prospective cohort studies with longer observation periods, is needed to assess the impact of the two screening interventions on morbidity and mortality.
RCT | Early postpartum IUD placement noninferior vs. placement at 6-8 weeks for complete expulsion, but not for partial expulsion
31 Mar, 2023 | 13:48h | UTCEarly vs Interval Postpartum Intrauterine Device Placement: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
News Release: Study: Risk of IUD Expulsion in Early Postpartum Placement – UC San Diego Health
Commentary: IUD Placement at Two to Four Weeks Postpartum Noninferior – HealthDay
Related:
Commentary on Twitter
Early IUD placement at 2 to 4 weeks postpartum compared with 6 to 8 weeks postpartum was noninferior for complete expulsion, but not partial expulsion. https://t.co/VMfWce3JJd pic.twitter.com/vdLrhCXa5Q
— JAMA (@JAMA_current) March 23, 2023
Study shows a slight breast cancer risk increase with progestogen-only birth control, comparable to combined oral methods
29 Mar, 2023 | 13:35h | UTCSummary: A UK study and meta-analysis examined breast cancer risk linked to hormonal contraceptives, emphasizing progestagen-only contraceptives in premenopausal women. Utilizing a nested case-control design with the Clinical Practice Research Datalink (CPRD), a primary care database, the study included 9,498 women under 50 diagnosed with invasive breast cancer between 1996 and 2017, and 18,171 closely matched controls. The meta-analysis merged CPRD findings with 12 observational studies on progestagen-only preparations.
The results revealed that current or recent use of combined oral contraceptives, oral progestagen-only contraceptives, injectable progestagen, and progestagen intrauterine devices all led to a similar increase in breast cancer risk. The 15-year absolute excess risk associated with five years of oral combined or progestagen-only contraceptive use ranged from 8 per 100,000 users aged 16-20 to 265 per 100,000 users aged 35-39. The study concluded that both contraceptive types were linked to a slight breast cancer risk increase, and these risks must be weighed against the benefits of contraceptive use during childbearing years.
News Release: Study finds similar association of progestogen-only and combined hormonal contraceptives with breast cancer risk – PLOS
Consensus Statement | Management of vaginal intraepithelial neoplasia
28 Mar, 2023 | 14:37h | UTC
RCT | Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause
23 Mar, 2023 | 13:01h | UTCFezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
70% of women experience hot flushes or night sweats during #menopause.
A new study investigates the role Fezolinetant, a non-hormonal treatment, could play in reducing these symptoms. https://t.co/zv4b9WU03h
— The Lancet (@TheLancet) March 15, 2023
Comparative study highlights women’s lower susceptibility to sudden cardiac arrest during sports
21 Mar, 2023 | 13:44h | UTCSummary: This study assessed the incidence, characteristics, and outcomes of sports-related sudden cardiac arrest (Sr-SCA) in women. Data from three European registries were analyzed, identifying 34,826 SCA cases between 2006 and 2017, with 760 cases (2.2%) being Sr-SCA, including 54 in women.
The average annual incidence of Sr-SCA in women was 0.19 per million, over 10 times lower than in men (2.63 per million). When extrapolated to the European population, this translates to 98 cases per year in women and 1,350 cases in men.
Characteristics, bystander response, time to defibrillation, and survival rates did not significantly differ between women and men. The findings highlight the considerably lower risk of Sr-SCA in women compared to men and should be considered when designing preparticipation screening strategies in the future.
Article: Incidence of Cardiac Arrest During Sports Among Women in the European Union – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentary: Incidence of Cardiac Arrest During Sports Among Women – American College of Cardiology
Commentary on Twitter
Women are at very low risk of cardiac arrest during sports: incidence in women was calculated to be 13 times lower than in men in 3 European registries, w/ no differences in profile, circumstances, mgmt or outcomes. https://t.co/CLl6amlIHO#JACC #CardioTwitter #SportsCardio pic.twitter.com/ADpakbwUKt
— JACC Journals (@JACCJournals) March 15, 2023
AACC Guidance document on cervical cancer detection: screening, surveillance, and diagnosis
16 Mar, 2023 | 13:21h | UTC
Review | Diagnosis and management of endometriosis
15 Mar, 2023 | 15:19h | UTCDiagnosis and management of endometriosis – Canadian Medical Association Journal
M-A | Risk of recurrence and reintervention after uterine-sparing interventions for symptomatic adenomyosis
15 Mar, 2023 | 15:05h | UTC
Update on current contraceptive options | A case-based discussion of efficacy, eligibility, and use
7 Mar, 2023 | 13:06h | UTC
RCT | Immediate vs. delayed urinary catheter removal following non-hysterectomy benign gynecological laparoscopy
3 Mar, 2023 | 13:55h | UTCSummary: This randomized clinical trial compared the rates of urinary retention and postoperative urinary tract infection between women with immediate vs. delayed removal of the indwelling catheter following benign gynecological laparoscopic surgery, excluding hysterectomy, pelvic floor, or surgeries with concomitant bowel procedures. A total of 693 women aged 18 years or older were randomized to immediate or delayed urinary catheter removal. The results showed an increased risk of urinary retention with immediate vs. delayed removal of the urinary catheter (8.2% vs. 4.2%), highlighting the need to ensure patients report normal voiding and emptying before discharge to reduce the need for readmission for management of urinary retention.
Article: Immediate versus delayed urinary catheter removal following non-hysterectomy benign gynecological laparoscopy: a randomised trial – BJOG (link to abstract – $ for full-text)
Related: Feasibility of immediate removal of urinary catheter after laparoscopic gynecological surgery for benign diseases: A meta-analysis of randomized controlled trials – Obstetrics & Gynecology (link to abstract – $ for full-text)
RCT | Efficacy of Fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause
3 Mar, 2023 | 13:28h | UTC
Cohort Study | Female hormone therapy and risk of intracranial hemorrhage from cerebral cavernous malformations
2 Mar, 2023 | 13:03h | UTCSummary: The study aimed to investigate the association between female hormone therapy (oral contraception or menopausal hormone therapy) and intracranial hemorrhage in female patients with cerebral cavernous malformations (CCM) using data from 2 large prospective cohort studies. The researchers analyzed data from 722 female patients with CCM and found that female hormone therapy use was associated with an increased risk of subsequent intracranial hemorrhage. The risk was more significant among female patients aged 10-44 years using oral contraceptives (adjusted hazard ratio 2·00, 95% CI 1·26-3·17; p=0·003). These findings raise questions about the safety of female hormone therapy in patients with cerebral cavernous malformation.
Article: Female Hormone Therapy and Risk of Intracranial Hemorrhage From Cerebral Cavernous Malformations: A Multicenter Observational Cohort Study – Neurology (link to abstract – $ for full-text – you can try this link for full-text)
Cohort Study | Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer
2 Mar, 2023 | 12:56h | UTCCommentary: Risk of Uterine Diseases, Cancers Up With Tamoxifen Treatment – HealthDay
Commentary on Twitter
Use of tamoxifen as an adjuvant hormone therapy for breast cancer was associated with an increased risk of endometrial polyps, hyperplasia, carcinoma, and other uterine cancers in Korean premenopausal women. https://t.co/JqnKjemjoW
— JAMA Network Open (@JAMANetworkOpen) November 29, 2022